Drug Trial Radar · NCT02730377
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jul 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,991
Actual
Start
Mar 28, 2016
Primary completion
Aug 5, 2019
Study completion Aug 12, 2019
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Apr 6, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
liraglutideDrug
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
alpha-glucosidase inhibitorsDrug
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
DPP-4 inhibitorsDrug
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
meglitinidesDrug
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
SGLT-2 inhibitorsDrug
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
sulphonylureaDrug
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
thiazolidinedionesDrug
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Inadequate Glycaemic ControlTime frame: Weeks 26-104
Locations
232 sites in 10 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Haleyville, Alabama
Novo Nordisk Investigational Site
Tuscumbia, Alabama
Novo Nordisk Investigational Site
Fountain Hills, Arizona
Novo Nordisk Investigational Site
Phoenix, Arizona
Novo Nordisk Investigational Site
Phoenix, Arizona
Novo Nordisk Investigational Site
Phoenix, Arizona
Novo Nordisk Investigational Site
Tempe, Arizona
Novo Nordisk Investigational Site
Tucson, Arizona
Novo Nordisk Investigational Site
Harrisburg, Arkansas
Novo Nordisk Investigational Site
Little Rock, Arkansas
Novo Nordisk Investigational Site
North Little Rock, Arkansas
Novo Nordisk Investigational Site
Searcy, Arkansas
Novo Nordisk Investigational Site
Alhambra, California
Novo Nordisk Investigational Site
Buena Park, California
Novo Nordisk Investigational Site
Carlsbad, California
Novo Nordisk Investigational Site
Coronado, California
Novo Nordisk Investigational Site
Costa Mesa, California
Novo Nordisk Investigational Site
Elk Grove, California
Novo Nordisk Investigational Site
Encinitas, California
Novo Nordisk Investigational Site
Huntington Beach, California
Novo Nordisk Investigational Site
La Mirada, California
Novo Nordisk Investigational Site
Lancaster, California
Novo Nordisk Investigational Site
Lomita, California
Novo Nordisk Investigational Site
Montclair, California
Novo Nordisk Investigational Site
Northridge, California
Novo Nordisk Investigational Site
Oxnard, California
Novo Nordisk Investigational Site
Rancho Cucamonga, California
Novo Nordisk Investigational Site
Riverside, California
Novo Nordisk Investigational Site
San Diego, California
Novo Nordisk Investigational Site
San Diego, California
Novo Nordisk Investigational Site
San Ramon, California
Novo Nordisk Investigational Site
Tustin, California
Novo Nordisk Investigational Site
Westminster, California
Novo Nordisk Investigational Site
Centennial, Colorado
Novo Nordisk Investigational Site
Centennial, Colorado
Novo Nordisk Investigational Site
Colorado Springs, Colorado
Novo Nordisk Investigational Site
Golden, Colorado
Novo Nordisk Investigational Site
Monument, Colorado
Novo Nordisk Investigational Site
Chiefland, Florida
Showing 40 of 232 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.